Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Net Margin (2017 - 2025)

Historic Net Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 373.3%.

  • Autolus Therapeutics' Net Margin changed N/A to 373.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 439.68%, marking a year-over-year increase of 22358300.0%. This contributed to the annual value of 2180.45% for FY2024, which is 100918100.0% up from last year.
  • As of Q3 2025, Autolus Therapeutics' Net Margin stood at 373.3%.
  • Over the past 5 years, Autolus Therapeutics' Net Margin peaked at 229.02% during Q2 2025, and registered a low of 14402966101.69% during Q3 2021.
  • Moreover, its 5-year median value for Net Margin was 2443.31% (2023), whereas its average is 1200259567.48%.
  • In the last 5 years, Autolus Therapeutics' Net Margin plummeted by 2000000000bps in 2021 and then skyrocketed by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Net Margin stood at 14402966101.69% in 2021, then surged by 100bps to 737.33% in 2022, then plummeted by -1432bps to 11292.86% in 2023, then tumbled by -743bps to 95193.1% in 2024, then skyrocketed by 100bps to 373.3% in 2025.
  • Its last three reported values are 373.3% in Q3 2025, 229.02% for Q2 2025, and 781.13% during Q1 2025.